Bromperidol
Based on 2 publication(s) in Google Scholar
Bromperidol (R-11333) possesses antipsychotic activity, with a high affinity for central dopamine receptors D2. Bromperidol can kill Mycobacteria in a synergistic manner with Spectinomycin.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.83%
- No. CAS: 10457-90-6
- Fòrmula: C21H23BrFNO2
- Peso molecular:420.32
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-14538
HaloperidolDopamine Receptor Antagonist -
HY-12987
PimozideDopamine Receptor Antagonist -
HY-15463
ImatinibTyrosine Kinases Inhibitor -
HY-A0019
PaliperidoneDopamine D2/5-HT2A Antagonist -
HY-14543
Sertindole5-HT/DA Receptor Antagonist -
HY-103093
ZotepineAntipsychotic Agent -
HY-B1470
Azaperoneα-Adrenoceptor/Dopamine Receptor Antagonist -
HY-101094
Ocaperidone5-HT2/Dopamine D2 Antagonist -
HY-B0462
Azelastine hydrochlorideHistamine 1 Antagonist
Publications Citing Use of MedChemExpress (MCE) Bromperidol
MoreVer todos los productos específicos de isoformas Dopamine Receptor
More
Actividad biológica
Descripciòn
IC50 & Target
|
D2 Receptor |
In Vivo
Bromperidol antagonises apomorphine-induced emesis and inhibits the conditioned avoidance response in dogs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 10457-90-6
-
Appearance Solid
-
Peso molecular 420.32
-
Fòrmula C21H23BrFNO2
-
Color White to yellow
-
SMILES
O=C(C1=CC=C(F)C=C1)CCCN2CCC(O)(C3=CC=C(Br)C=C3)CC2
-
Synonyms
R-11333
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Pharmacology
2019;104(1-2):43-50. PMID: 31067549 -
Biol Pharm Bull
Inhibitory Effects of Antipsychotics on the Contractile Response to Acetylcholine in Rat Urinary Bladder Smooth Muscles. [Abstract]2021;44(8):1140-1150. PMID: 34334499
Solvente y solubilidad
In Vitro:
DMSO : 50 mg/mL (118.96 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.95 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (270 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Benfield P, et al. Bromperidol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in psychoses. Drugs. 1988 Jun;35(6):670-84. [Content Brief]
[2]. Ramón-García S, et al. Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen. Antimicrob Agents Chemother. 2011 Aug;55(8):3861-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3791 mL | 11.8957 mL | 23.7914 mL | 59.4785 mL |
| 5 mM | 0.4758 mL | 2.3791 mL | 4.7583 mL | 11.8957 mL | |
| 10 mM | 0.2379 mL | 1.1896 mL | 2.3791 mL | 5.9478 mL | |
| 15 mM | 0.1586 mL | 0.7930 mL | 1.5861 mL | 3.9652 mL | |
| 20 mM | 0.1190 mL | 0.5948 mL | 1.1896 mL | 2.9739 mL | |
| 25 mM | 0.0952 mL | 0.4758 mL | 0.9517 mL | 2.3791 mL | |
| 30 mM | 0.0793 mL | 0.3965 mL | 0.7930 mL | 1.9826 mL | |
| 40 mM | 0.0595 mL | 0.2974 mL | 0.5948 mL | 1.4870 mL | |
| 50 mM | 0.0476 mL | 0.2379 mL | 0.4758 mL | 1.1896 mL | |
| 60 mM | 0.0397 mL | 0.1983 mL | 0.3965 mL | 0.9913 mL | |
| 80 mM | 0.0297 mL | 0.1487 mL | 0.2974 mL | 0.7435 mL | |
| 100 mM | 0.0238 mL | 0.1190 mL | 0.2379 mL | 0.5948 mL |
Bromperidol Related Classifications
HY-B0901 Related Classifications
Powered by Bioz